Reversal Processes by Dynamic Therapies: Pathophysiology, Biomarkers and Integrative Applications for Endometriosis: Case Report
Sheryene N Tejeda *
Biomedical Engineering Society, Association for Women in Science and National Medical Association, United States and Medicinal Technologies, Florida, United States.
*Author to whom correspondence should be addressed.
Abstract
Introduction: This study's goal was to understand the pathophysiology of endometriosis and its epigenetic biomarkers that are useful in proposing integrative therapies for improved health outcomes. Current conventional therapies have been ineffective in treating endometrial abnormalities observed in patients diagnosed with the disease.
Patient Concerns: The endogenic treatment protocol that was based on the integrated process of reversal therapy was provided to thirty female participants enrolled in the study. Resulting fertility issues due to the disease renders a significant percentage of this population nulliparous. Literature is exhausted with research to establish relative pathogenicity of the monospecific disease as it corresponds to its molecular characteristics, symptoms, and progression.
Diagnosis: Angiogenesis was found to be a characteristic mechanism during the development of endometriosis resulting from a mutation of the GnRH gene thus compromising JEG-3 cell operations. Upregulated immune-related factors and functionally prevalent angiogenesis predisposes this population to acquire abnormal endometrial outcomes.
Interventions: A monotherapeutic approach was utilized consisting of a 3 part biomedical treatment protocol applied for 90 days to obtain menstral process improvements by decreasing the incidence of endometriosis and corresponding infertility.
Outcomes: Proposed mechanism of action provided by The Tejeda Equation (∑(σX GnRH ⇒ JEG3f )+ (σα ^βER ) ∴ NR3A1 ≥ 300-437pg/ml e (τ +30dy)∆ δEEC) permitted development of applied biomedical treatment protocol Fig.4. The protocols therapeutic matrix addressed all aspects of Bis4 by reversal of the mutated GnRH gene, restoration of JEG-3 cells and diminished endometrial lesions Fig.1. Corresponding results proved favorably.
Conclusion: Some significant genetic factors that are critical contributors to endometriosis have remained undiscovered. Continued research will be pursued that can assist in developing alternate diverse treatment strategies for the affected population.
Keywords: Pathophysiology, integrative therapies, reversal therapy, epigenetic biomarkers, infertility, endometriosis
How to Cite
Downloads
References
Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: Pathogenesis and treatment. Nature Reviews Endocrinology. 2014;10(5): 261-275.
Ghiasi M, Kulkarni MT, Missmer SA. Is endometriosis more common and more severe than it was 30 years ago? Journal of Minimally Invasive Gynecology. 2020; 27(2):452-461.
Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertility and Sterility. 2012;98(3):511-519.
Bozdag G. Recurrence of endometriosis: Risk factors, mechanisms and biomarkers. Women's Health. 2015;11(5):693-699.
Li XY, Chao XP, Leng JH, Zhang W, Zhang JJ, Dai Y, Wu YS. Risk factors for postoperative recurrence of ovarian endometriosis: long-term follow-up of 358 women. Journal of Ovarian Research. 2019; 12(1):1-10.
Falcone T, Flyckt R. Clinical management of endometriosis. Obstetrics & Gynecology. 2018; 131(3):557-571.
Davis-Kankanamge C. The Holistic Approach to Managing Adolescent Endometriosis. In Endometriosis in Adolescents. Springer, Cham. 2020;679-684.
Cousins FL, Filby CE, Gargett CE. Endometrial stem/progenitor cells-their role in endometrial repair and regeneration. Frontiers in Reproductive Health. 2022;119.
Zubrzycka A, Zubrzycki M, Perdas E, Zubrzycka M. Genetic, epigenetic, and steroidogenic modulation mechanisms in endometriosis. Journal of Clinical Medicine. 2020;9(5):1309.
LanišnikRižner T. Noninvasive biomarkers of endometriosis: Myth or reality? Expert Review of Molecular Diagnostics. 2014; 14(3):365-385.
Lu W, Xia YH, Qu JJ. He YY, Li BL, Lu C, Wan XP. p21-activated kinase 4 regulation of endometrial cancer cell migration and invasion involves the ERK1/2 pathway mediated MMP-2 secretion. Neoplasma. 2013;060(5):493-503.
Kim SH, Kim SR, Ihm HJ, Oh YS, Chae HD, Kim CH, Kang BM. Regulation of P21-activated kinase-4 by progesterone and tumor necrosis factor-α in human endometrium and its increased expression in advanced-stage endometriosis. The Journal of Clinical Endocrinology & Metabolism. 2013;98(2): E238-E248.
Kocbek V, Vouk K, Mueller MD, Rižner TL, Bersinger NA. Elevated glycodelin-A concentrations in serum and peritoneal fluid of women with ovarian endometriosis. Gynecological Endocrinology. 2013;29(5):455-459.
Kuokkanen S, Chen B, Ojalvo L, Benard L, Santoro N, Pollard JW. Genomic profiling of microRNAs and messenger RNAs reveals hormonal regulation in microRNA expression in human endometrium. Biology of Reproduction. 2010;82(4):791-801.
Tamburro S, Canis M, Albuisson E, Dechelotte P, Darcha C, Mage G. Expression of transforming growth factor β1 in nerve fibers is related to dysmenorrhea and laparoscopic appearance of endometriotic implants. Fertility and Sterility. 2003;80(5):1131-1136.
Wu Y, Starzinski-Powitz A, Guo SW. Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalised endometriotic cells. Reproductive Sciences. 2007;14(4):374-382.
Kitawaki JHK. Progesterone induction of 17 -hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the BioMed Research International 13 endometrium of estrogen- dependent benign diseases but not in normal endometrium. Journal of Clinical Endocrinology and Metabolism. 2000; 3292–3296.
Noble LS, Takayama K, Zeitoun KM, Putman JM, Johns DA, Hinshelwood MM, Bulun SE. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. The Journal of Clinical Endocrinology & Metabolism. 1997;82(2):600-606.
Gołąbek A, Kowalska K, Olejnik A. Polyphenols as a Diet Therapy Concept for Endometriosis—Current Opinion and Future Perspectives. Nutrients. 2021;13 (4):1347.
Tosti C, Biscione A, Morgante G, Bifulco G, Luisi S, Petraglia F. Hormonal therapy for endometriosis: from molecular research to bedside. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2017; 209:61-66.
Dai Y, Li X, Shi J, Leng J. A review of the risk factors, genetics and treatment of endometriosis in Chinese women: a comparative update. Reproductive Health. 2018;15(1):1-12.
Reid R, Steel A, Wardle J, Adams J. Naturopathic medicine for the management of endometriosis, dysmenorrhea, and menorrhagia: a content analysis. The Journal of Alternative and Complementary Medicine. 2019;25(2):202-226.
Redmond R, Steel A, Wardle J, Adams J. Naturopathy utilisation by Australian women with diagnosed endometriosis: A cross-sectional survey. Complementary Therapies in Clinical Practice. 2022; 101539.
Neilson V. Integrative Endometriosis: New treatment strategies from theory to clinical application with nutraceuticals and homeopathic medicines article information. Asian Journal of Ethnopharmacology and Medicinal Food. 2018;4(2). ISSN: 2455-4812.
Khan KN, Kitajima M, Hiraki K, Fujishita A, Nakashima M, Ishimaru T, Masuzaki H. Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma. Human Reproduction. 2010;25 (11):2878-2890.